These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

956 related items for PubMed ID: 15804727

  • 1. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
    [Abstract] [Full Text] [Related]

  • 2. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM, Fini M.
    Int J Fertil Womens Med; 2001 Mar; 46(5):248-56. PubMed ID: 11720197
    [Abstract] [Full Text] [Related]

  • 3. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM, Naftolin F, Brinton EA, Judelson DR.
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [Abstract] [Full Text] [Related]

  • 4. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [Abstract] [Full Text] [Related]

  • 5. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.
    Mohandas B, Mehta JL.
    Curr Opin Cardiol; 2007 Sep; 22(5):434-42. PubMed ID: 17762545
    [Abstract] [Full Text] [Related]

  • 6. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM, Vitale C, Fini M.
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [Abstract] [Full Text] [Related]

  • 7. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA.
    Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
    [Abstract] [Full Text] [Related]

  • 8. Preserving cardiovascular benefits of hormone replacement therapy.
    Bush TL.
    J Reprod Med; 2000 Mar; 45(3 Suppl):259-73. PubMed ID: 10756507
    [Abstract] [Full Text] [Related]

  • 9. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [Abstract] [Full Text] [Related]

  • 10. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Menopause; 2006 Jun; 13(1):139-47. PubMed ID: 16607110
    [Abstract] [Full Text] [Related]

  • 11. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI.
    Clanget C, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J.
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):529-33. PubMed ID: 16235155
    [Abstract] [Full Text] [Related]

  • 12. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2006 Apr 01; 163(7):589-99. PubMed ID: 16484450
    [Abstract] [Full Text] [Related]

  • 13. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones.
    Rossouw JE.
    Maturitas; 2005 May 16; 51(1):51-63. PubMed ID: 15883110
    [Abstract] [Full Text] [Related]

  • 14. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD.
    Ann N Y Acad Sci; 2005 Jun 16; 1052():57-74. PubMed ID: 16024751
    [Abstract] [Full Text] [Related]

  • 15. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct 16; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 16. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 17. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK, Governale LA.
    Pharmacoepidemiol Drug Saf; 2005 Mar 16; 14(3):171-6. PubMed ID: 15386701
    [Abstract] [Full Text] [Related]

  • 18. HRT dosing regimens: continuous versus cyclic-pros and cons.
    Shoupe D.
    Int J Fertil Womens Med; 2001 Mar 16; 46(1):7-15. PubMed ID: 11294619
    [Abstract] [Full Text] [Related]

  • 19. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
    Sammartino A, Cirillo D, Mandato VD, Di Carlo C, Nappi C.
    J Endocrinol Invest; 2005 Mar 16; 28(10 Suppl):80-4. PubMed ID: 16550729
    [Abstract] [Full Text] [Related]

  • 20. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE.
    Ann N Y Acad Sci; 2006 Nov 16; 1089():444-53. PubMed ID: 17261787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.